Yann Kieffer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Recognitions
Yann Kieffer has a total of 278 co-authors. Here are the top co-authors by number of shared publications:
- Fatima Mechta-Grigoriou
Institut Curie, Stress and Cancer Laboratory, Equipe labélisée par la Ligue Nationale contre le Cancer, PSL Research University, Paris, France
94 shared publications - Anne Vincent-Salomon
Institut Curie, PSL University
76 shared publications - Claire Bonneau
Institut Curie, Department of Gynecology, Saint-Cloud, France
72 shared publications - Christophe Le Tourneau
Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France
59 shared publications - Hugo Croizer
Institut Curie, Stress and Cancer Laboratory, Equipe labélisée par la Ligue Nationale contre le Cancer, PSL Research University, Paris, France
59 shared publications - Maria Carla Parrini
INSERM U830, Institut Curie, Université PSL
59 shared publications
Latest Publications
- Open Access
- 7 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Nuclear localization of the glutaminyl-tRNA synthetase QARS reveals its role in DNA damage response in ovarian cancer
Uncovering novel mechanisms controlling DNA damage response (DDR) is essential to better understand the molecular features of high-grade serous ovarian cancers (HGSOC), which remain a clinical challenge. Here, we demonstrate that the glutaminyl-tRNA-synthetase QARS is a key player in DDR. We show that QARS is regulated at translational level by the MAPK pathway in HGSOC and controls homologous recombination (HR) through a translation-independent mechanism. Analyses combining RNA sequencing, immunohistochemistry, proteomic data and functional assays from HGSOC patient cohorts and relevant cellular models reveal that QARS promotes DNA repair via the HR pathway. Interestingly, we uncover that QARS is located in the nucleus and is enriched at chromatin upon DNA damage. Nuclear QARS controls HR by interacting with the nuclear autoantigen SP100, a major component of PML-nuclear bodies (PML-NB), that are regulatory hubs for DNA repair proteins. Our data highlight nuclear functions and mechanisms for QARS involving SP100, PML-NB and MRE11 that enhance HR in HGSOC.
- 7 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessNuclear localization of the glutaminyl-tRNA synthetase QARS reveals its role in DNA damage response in ovarian cancer
Uncovering novel mechanisms controlling DNA damage response (DDR) is essential to better understand the molecular features of high-grade serous ovarian cancers (HGSOC), which remain a clinical challenge. Here, we demonstrate that the glutaminyl-tRNA-synthetase QARS is a key player in DDR. We show that QARS is regulated at translational level by the MAPK pathway in HGSOC and controls homologous recombination (HR) through a translation-independent mechanism. Analyses combining RNA sequencing, immunohistochemistry, proteomic data and functional assays from HGSOC patient cohorts and relevant cellular models reveal that QARS promotes DNA repair via the HR pathway. Interestingly, we uncover that QARS is located in the nucleus and is enriched at chromatin upon DNA damage. Nuclear QARS controls HR by interacting with the nuclear autoantigen SP100, a major component of PML-nuclear bodies (PML-NB), that are regulatory hubs for DNA repair proteins. Our data highlight nuclear functions and mechanisms for QARS involving SP100, PML-NB and MRE11 that enhance HR in HGSOC.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Video S2 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
ToC mono-culture of MDA-MB-231, time length 72h, 2μM Doxorubicin. Scale bar = 100 μm.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessVideo S2 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
ToC mono-culture of MDA-MB-231, time length 72h, 2μM Doxorubicin. Scale bar = 100 μm.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 7 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
ECM-myCAFs induce SRC kinase activity in TNBC cells. A, Kinome tree depicting upregulation and downregulation of kinase family activities in MDA-MB-231 cells upon 42 hours of ECM-myCAF transwell coculture (n = 2 different patient-derived ECM-myCAFs). B, Western blot showing pSRCTyr416, total SRC, G0S2, and β-actin protein levels in MDA-MB-231 cells after 42 hours of transwell culture without or with ECM-myCAFs (n = 4 different patient-derived ECM-myCAFs). C and D, Quantification of pSRC and G0S2 levels from B. pSRC and G0S2 protein levels in MDA-MB-231 in coculture with ECM-myCAF are normalized to their respective protein levels in monoculture. Values are represented as the mean ± SEM. E, Venn diagram showing the overlap between TFs predicted to be activated in MDA-MB-231 cells upon ECM-myCAF coculture in ToC and those known to positively regulate G0S2 transcription (as shown in Fig. 5F), together with TFs identified by Ji and colleagues (62) as regulated by v-SRC. F, Western blot showing pSRC, total SRC, G0S2, and β-actin protein levels at indicated time points in MDA-MB-231 cells silenced (siG0S2) or not (siCTRL) for G0S2. G, Quantification of F. pSRC level was normalized to siCTRL at 48 hours. H, Representative Western blot of MDA-MB-231 cells after treatment with increasing concentrations of the SRC family kinases inhibitor dasatinib. I, Quantification of G0S2 protein levels upon 48 hours of dasatinib (50 nmol/L) treatment normalized to DMSO control (n = 2 independent experiments). Values are represented as the mean ± SEM. J, Automated quantification of MDA-MB-231 survival ± ECM-myCAFs ± doxorubicin ± dasatinib (n = 3 independent experiments using three different patient-derived ECM-myCAFs; n = 3 videos analyzed per condition). C, D, and I, Statistical significance was assessed by the Mann–Whitney test; J,P values from two-sided Wilcoxon rank-sum test. E, Created in BioRender. Mechta-Grigoriou, F. (2025) https://BioRender.com/l3pzirw.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 7 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
ECM-myCAFs induce SRC kinase activity in TNBC cells. A, Kinome tree depicting upregulation and downregulation of kinase family activities in MDA-MB-231 cells upon 42 hours of ECM-myCAF transwell coculture (n = 2 different patient-derived ECM-myCAFs). B, Western blot showing pSRCTyr416, total SRC, G0S2, and β-actin protein levels in MDA-MB-231 cells after 42 hours of transwell culture without or with ECM-myCAFs (n = 4 different patient-derived ECM-myCAFs). C and D, Quantification of pSRC and G0S2 levels from B. pSRC and G0S2 protein levels in MDA-MB-231 in coculture with ECM-myCAF are normalized to their respective protein levels in monoculture. Values are represented as the mean ± SEM. E, Venn diagram showing the overlap between TFs predicted to be activated in MDA-MB-231 cells upon ECM-myCAF coculture in ToC and those known to positively regulate G0S2 transcription (as shown in Fig. 5F), together with TFs identified by Ji and colleagues (62) as regulated by v-SRC. F, Western blot showing pSRC, total SRC, G0S2, and β-actin protein levels at indicated time points in MDA-MB-231 cells silenced (siG0S2) or not (siCTRL) for G0S2. G, Quantification of F. pSRC level was normalized to siCTRL at 48 hours. H, Representative Western blot of MDA-MB-231 cells after treatment with increasing concentrations of the SRC family kinases inhibitor dasatinib. I, Quantification of G0S2 protein levels upon 48 hours of dasatinib (50 nmol/L) treatment normalized to DMSO control (n = 2 independent experiments). Values are represented as the mean ± SEM. J, Automated quantification of MDA-MB-231 survival ± ECM-myCAFs ± doxorubicin ± dasatinib (n = 3 independent experiments using three different patient-derived ECM-myCAFs; n = 3 videos analyzed per condition). C, D, and I, Statistical significance was assessed by the Mann–Whitney test; J,P values from two-sided Wilcoxon rank-sum test. E, Created in BioRender. Mechta-Grigoriou, F. (2025) https://BioRender.com/l3pzirw.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Video S11 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
ToC mono-culture of MDA-MB-436, time length 72h, 1μM Paclitaxel. Scale bar = 100 μm.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessVideo S11 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
ToC mono-culture of MDA-MB-436, time length 72h, 1μM Paclitaxel. Scale bar = 100 μm.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
Primary ECM-myCAFs display a heterogeneous response to doxorubicin. A and B, Representative images of ECM-myCAFs from patient #2 (A) and patient #3 (B) ± doxorubicin at acquisition start (0 hours) and 72 hours after culture in ToC. Scale bar, 100 μm. White arrows, living cells; red arrows, dead cells. C, ECM-myCAF (from three different patients) apoptosis rate ± MDA-MB-231 ± doxorubicin (n = 3 independent experiments; n = 3 videos per condition). D, Alive ECM-myCAF (from three different patients) ± MDA-MB-231 ± doxorubicin normalized to alive cells at acquisition start (0 hours; n = 3 independent experiments; n = 3 videos per condition). E and F, ECM-myCAF apoptosis rate and alive cells (combining the three patients) ± MDA-MB-231 ± doxorubicin. G, Representative images of ECM-myCAFs under paclitaxel treatment at acquisition start (0 hours) and 72 hours after culture in ToC. Scale bar, 100 μm. White arrows, living cells; red arrows, dead cells. H, Manual quantification of ECM-myCAF apoptosis rate (combining three patients) ± MDA-MB-231 ± paclitaxel. I, Alive ECM-myCAF (combining three patients) ± MDA-MB-231 ± paclitaxel normalized to alive cells at acquisition start (0 hours). Data are represented as the mean ± SEM. Statistical differences were assessed by the Wilcoxon matched-pair signed-rank test.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
Primary ECM-myCAFs display a heterogeneous response to doxorubicin. A and B, Representative images of ECM-myCAFs from patient #2 (A) and patient #3 (B) ± doxorubicin at acquisition start (0 hours) and 72 hours after culture in ToC. Scale bar, 100 μm. White arrows, living cells; red arrows, dead cells. C, ECM-myCAF (from three different patients) apoptosis rate ± MDA-MB-231 ± doxorubicin (n = 3 independent experiments; n = 3 videos per condition). D, Alive ECM-myCAF (from three different patients) ± MDA-MB-231 ± doxorubicin normalized to alive cells at acquisition start (0 hours; n = 3 independent experiments; n = 3 videos per condition). E and F, ECM-myCAF apoptosis rate and alive cells (combining the three patients) ± MDA-MB-231 ± doxorubicin. G, Representative images of ECM-myCAFs under paclitaxel treatment at acquisition start (0 hours) and 72 hours after culture in ToC. Scale bar, 100 μm. White arrows, living cells; red arrows, dead cells. H, Manual quantification of ECM-myCAF apoptosis rate (combining three patients) ± MDA-MB-231 ± paclitaxel. I, Alive ECM-myCAF (combining three patients) ± MDA-MB-231 ± paclitaxel normalized to alive cells at acquisition start (0 hours). Data are represented as the mean ± SEM. Statistical differences were assessed by the Wilcoxon matched-pair signed-rank test.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
G0S2 expression is elevated in cancer cells following direct ECM-myCAF co-culture in 2D conditions
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
G0S2 expression is elevated in cancer cells following direct ECM-myCAF co-culture in 2D conditions
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Video S7 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
ToC mono-culture of MDA-MB-436, time length 72h, no treatment. Scale bar = 100 μm.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessVideo S7 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
ToC mono-culture of MDA-MB-436, time length 72h, no treatment. Scale bar = 100 μm.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
Primary ECM-myCAFs protect TNBC cell lines from death under doxorubicin and paclitaxel treatment in a 3D ToC model. A, Schematic overview of 3D ToC generation from primary breast cancer–derived ECM-myCAF and TNBC cell lines. B, UMAP showing high expression of FAP+ CAF (also referred to as CAF-S1) and ECM-myCAF gene signatures (10) in ECM-myCAF, validating their identity after 3D ToC culture assessed by scRNA-seq (n = 9,651 cells from two independent experiments using two different patient-derived ECM-myCAFs). C, Representative images of MDA-MB-231 ± ECM-myCAF ± doxorubicin or paclitaxel treatment at acquisition start (0 hours) and 72 hours after culture in ToC. Scale bar, 100 μm. White arrows, cancer cells; yellow arrows, ECM-myCAFs. D, Manual quantification of live MDA-MB-231 ± ECM-myCAF ± doxorubicin normalized to live cells at acquisition start (0 hours; n = 3 independent experiments using three different patient-derived ECM-myCAFs; n = 3 videos per condition). E, Manual quantification of MDA-MB-231 apoptosis ± ECM-myCAF ± doxorubicin (n = 3 independent experiments using three different patient-derived ECM-myCAFs; n = 3 videos per condition). F and G, Automated quantification of MDA-MB-231 apoptosis index (F) and survival (G) ± ECM-myCAF ± doxorubicin (n = 4 independent experiments using four different patient-derived ECM-myCAFs; n = 3 videos per condition). H and I, Manual quantification of MDA-MB-231 apoptosis index (H) and survival (I) ± ECM-myCAF ± paclitaxel (n = 3 independent experiments using three different patient-derived ECM-myCAFs; n = 3 videos per condition). J and K, Automated quantification of MDA-MB-436 apoptosis index (J) and survival (K) ± ECM-myCAF ± doxorubicin (n = 2 independent experiments using two different patient-derived ECM-myCAFs; n = 3 videos per condition). L and M, Manual quantification of MDA-MB-436 apoptotic index (L) and survival (M) ± ECM-myCAF ± paclitaxel (n = 2 independent experiments using two different patient-derived ECM-myCAFs; n = 3 videos per condition). N, Representative images displaying typical ECM-myCAF and CAP fibroblast morphology. O and P, Automated quantification of MDA-MB-231 apoptosis index (O) and survival (P) ± CAP ± doxorubicin (n = 3 videos per condition). All data are represented as the mean ± SEM. Statistical differences were assessed by the Wilcoxon matched-pair signed-rank test. A, Created in BioRender. Mechta-Grigoriou, F. (2025) https://BioRender.com/fcjaht2.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
Primary ECM-myCAFs protect TNBC cell lines from death under doxorubicin and paclitaxel treatment in a 3D ToC model. A, Schematic overview of 3D ToC generation from primary breast cancer–derived ECM-myCAF and TNBC cell lines. B, UMAP showing high expression of FAP+ CAF (also referred to as CAF-S1) and ECM-myCAF gene signatures (10) in ECM-myCAF, validating their identity after 3D ToC culture assessed by scRNA-seq (n = 9,651 cells from two independent experiments using two different patient-derived ECM-myCAFs). C, Representative images of MDA-MB-231 ± ECM-myCAF ± doxorubicin or paclitaxel treatment at acquisition start (0 hours) and 72 hours after culture in ToC. Scale bar, 100 μm. White arrows, cancer cells; yellow arrows, ECM-myCAFs. D, Manual quantification of live MDA-MB-231 ± ECM-myCAF ± doxorubicin normalized to live cells at acquisition start (0 hours; n = 3 independent experiments using three different patient-derived ECM-myCAFs; n = 3 videos per condition). E, Manual quantification of MDA-MB-231 apoptosis ± ECM-myCAF ± doxorubicin (n = 3 independent experiments using three different patient-derived ECM-myCAFs; n = 3 videos per condition). F and G, Automated quantification of MDA-MB-231 apoptosis index (F) and survival (G) ± ECM-myCAF ± doxorubicin (n = 4 independent experiments using four different patient-derived ECM-myCAFs; n = 3 videos per condition). H and I, Manual quantification of MDA-MB-231 apoptosis index (H) and survival (I) ± ECM-myCAF ± paclitaxel (n = 3 independent experiments using three different patient-derived ECM-myCAFs; n = 3 videos per condition). J and K, Automated quantification of MDA-MB-436 apoptosis index (J) and survival (K) ± ECM-myCAF ± doxorubicin (n = 2 independent experiments using two different patient-derived ECM-myCAFs; n = 3 videos per condition). L and M, Manual quantification of MDA-MB-436 apoptotic index (L) and survival (M) ± ECM-myCAF ± paclitaxel (n = 2 independent experiments using two different patient-derived ECM-myCAFs; n = 3 videos per condition). N, Representative images displaying typical ECM-myCAF and CAP fibroblast morphology. O and P, Automated quantification of MDA-MB-231 apoptosis index (O) and survival (P) ± CAP ± doxorubicin (n = 3 videos per condition). All data are represented as the mean ± SEM. Statistical differences were assessed by the Wilcoxon matched-pair signed-rank test. A, Created in BioRender. Mechta-Grigoriou, F. (2025) https://BioRender.com/fcjaht2.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Video S4 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
ToC co-culture of MDA-MB-231 with ECM-myCAF, time length 72h, 2μM Doxorubicin. Scale bar = 100 μm.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessVideo S4 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
ToC co-culture of MDA-MB-231 with ECM-myCAF, time length 72h, 2μM Doxorubicin. Scale bar = 100 μm.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Video S1 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
ToC mono-culture of MDA-MB-231, time length 72h, no treatment. Cancer cells are stained in red, cells turning green indicate apoptotic cells. Scale bar = 100 μm.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessVideo S1 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
ToC mono-culture of MDA-MB-231, time length 72h, no treatment. Cancer cells are stained in red, cells turning green indicate apoptotic cells. Scale bar = 100 μm.